EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Coronavirus disease 2019 infection reduces EGFR ‐ TKI efficacy in non‐small cell lung carcinoma: Real‐world evidence from a multicenter propensity‐matched cohort

Wenjie Tang, Xiaoxuan Hou, Li Li, Hanxi Zhao, Xiaoyong Tang, Wanqi Zhu, Xiaohui Yan, Jing Liu, Qian Wu, Zhu Qiao, Shanliang Hu, Mingwei Zhang und 2 weitere

International Journal of Cancer · 01.08.2026 · 159 (3) · 699-708

DOI: 10.1002/ijc.70444 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, online erschienen am 20.03.2026. Verfasst von Wenjie Tang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences,…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, COVID-19, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shandong Province, Shandong Provincial Postdoctoral Science Foundation, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coronavirus disease 2019 (COVID‐19) remains a global health threat, particularly for patients with cancer, who experience greater susceptibility and worse outcomes. Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) is standard first‐line therapy for advanced EGFR‐mutated non‐small cell lung carcinoma (NSCLC). However, the impact of COVID‐19 on TKI efficacy remains unclear. This multicenter retrospective study included patients with stage IV EGFR‐mutated NSCLC who received first‐line EGFR‐TKI treatment at four Chinese hospitals. Leveraging China's policy change (December 2022), we compared a pre‐pandemic COVID‐19‐negative cohort (January 2019–November 2022) with a COVID‐19‐positive cohort (January–June 2023). After 1:1 propensity score matching (PSM), Kaplan–Meier and Cox regression analyses evaluated progression‐free survival (PFS) and prognostic factors. Among 711 patients (median follow‐up, 37.90 months), the COVID‐19‐negative group had significantly longer median PFS (18.17 vs. 12.89 months; p = .001). After PSM, we analyzed 426 well‐matched patients (213/cohort). Before and after matching, COVID‐19‐negative patients exhibited better PFS with all EGFR‐TKI generations (unmatched: p 1st

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCOVID-19Lung NeoplasmsProtein Kinase InhibitorsAgedFemaleHumansMaleMiddle AgedChinaErbB ReceptorsPrognosisProgression-Free SurvivalPropensity ScoreRetrospective StudiesSARS-CoV-2

Stichwörter der Autor:innen

COVID‐19EGFR‐TKINSCLCSARS‐CoV‐2propensity score matching

Substanzen

EGFR protein, humanErbB ReceptorsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
  • Medical Integration and Practice Center, Shandong University, Jinan, Shandong, China.
  • Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
  • Department of Radiation Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui, China.
  • Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
  • Department of Science and Education, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.

ORCID-Profile: Peng Xie

Förderung

  • Natural Science Foundation of Shandong Province
  • Shandong Provincial Postdoctoral Science Foundation
  • China Postdoctoral Science Foundation
  • Xinrui Cancer Supportive Treatment Foundation
  • Projects of Medical and Health Technology Development Program in Shandong Province
  • Beijing Science And Technology Innovation Medical Development Foundation
  • Wu Jieping Medical Foundation
  • Jinan Science and Technology Innovation Plan of Clinical Medicine

Zitieren

APA

Tang, W., Hou, X., Li, L., Zhao, H., Tang, X., Zhu, W., Yan, X., Liu, J., Wu, Q., Qiao, Z., Hu, S., Zhang, M., Li, X., & Xie, P. (2026). Coronavirus disease 2019 infection reduces EGFR ‐ TKI efficacy in non‐small cell lung carcinoma: Real‐world evidence from a multicenter propensity‐matched cohort. International Journal of Cancer, 159(3), 699-708. https://doi.org/10.1002/ijc.70444

Vancouver

Tang W, Hou X, Li L, Zhao H, Tang X, Zhu W, et al. Coronavirus disease 2019 infection reduces EGFR ‐ TKI efficacy in non‐small cell lung carcinoma: Real‐world evidence from a multicenter propensity‐matched cohort. International Journal of Cancer. 2026;159(3):699-708. doi:10.1002/ijc.70444

BibTeX
@article{Tang2026,
  author = {Tang, Wenjie and Hou, Xiaoxuan and Li, Li and Zhao, Hanxi and Tang, Xiaoyong and Zhu, Wanqi and Yan, Xiaohui and Liu, Jing and Wu, Qian and Qiao, Zhu and Hu, Shanliang and Zhang, Mingwei and Li, Xiaolin and Xie, Peng},
  title = {Coronavirus disease 2019 infection reduces EGFR ‐ TKI efficacy in non‐small cell lung carcinoma: Real‐world evidence from a multicenter propensity‐matched cohort},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {159},
  number = {3},
  pages = {699--708},
  doi = {10.1002/ijc.70444}
}
Kostenlos starten →